Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Systolic blood pressure \< 180 mmHg
90 mmHg ≤ Diastolic blood pressure \< 110 mmHg
You may not be if
Pregnancy or lactation. Women of child bearing potential (not post-menopausal) should be using a reliable contraceptive method
Known or suspected secondary hypertension (e.g., coarctation of aorta, renovascular stenosis, etc.)
Presence of clinically significant ventricular or supraventricular arrhythmias, or second or third degree atrioventricular block, or sick sinus syndrome
ALAT\[SGPT\]\>2 times of upper limit，
ASAT\[SGOT\]\>2 times of upper limit
Patients with known renal disease
Serum potassium \> normal upper limit
Uncontroled BD（FBG\>10mmol/L or PBG\>12.22mmol/L)
Patients treated with tricyclic antidepressants
Clinical hematological disease.
Patients with a history of irbesartan, or hydrochlorothiazide sensitivity defined as irbesartan, or hydrochlorothiazide discontinuation due to medically significant adverse effects.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population
